Apnimed (APMD) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.42
- Estimate
- -$0.34
- Surprise
- -22.5%
- Revenue (period 2026-06-30)
- $12.1M
- Score at report (before → after)
- 6.1 → 6.0/10
Revenue source: xbrl.
How the report landed
Apnimed (APMD) reported a wider loss than forecast — adjusted EPS of -$0.42 against the -$0.34 estimate (a 22.5% shortfall). TrendMatrix's engine moved from Sell (6.1/10) to Buy (Wait) at 6.0/10 after the report.
Coverage in the report window
- Apnimed Q2 EPS $3.91 Beats $(0.34) Estimate, Sales $12.080M — benzinga, 2026-09-08
Where TrendMatrix's rating stands now
TrendMatrix currently rates APMD Sell at 5.0/10.
0 of the last 1 quarters beat the estimate; this quarter's -22.5% surprise compares with a -22.5% four-quarter average. Next scheduled report: 2026-11-11.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Attractive valuation
What argues against it
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2)
- Leverage penalty (D/E 1.2): -0.5
- Weak overall score: 5.0/10
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $21.51
- Price target
- $42.78
- Stop
- $20.00
- Upside to target
- +98.9%
- Reward-to-risk
- 6.6:1
Model outputs from TrendMatrix’s engine as of 2026-10-05 — shown for context, not personalized investment advice.
APMD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $895.5M
- P/E (fwd)
- -5.4
- P/E (ttm)
- 3.8
- 52-week range
- $16.12–$35.29
- Off 52-week high
- 39.0%
- RSI (14)
- 39
- Volume vs avg
- 1.08×
- Score today
- 5.0/10